Flecainide Use in Older Adults: Safety, Contraindications, and Monitoring

Adverse Effects in Older Adults

In patients aged ≥ 65 years receiving flecainide, dizziness occurs in approximately 18.9 % of individuals (observational cohort)【1】.
Visual disturbances (e.g., blurred vision, difficulty focusing) are reported in about 15.9 % of older adults on flecainide (observational data)【2】.
Dyspnea is observed in roughly 10.3 % of elderly patients treated with flecainide (prospective study)【3】.
Headache affects about 9.6 % of this population (same prospective study)【3】.
Nausea occurs in approximately 8.9 % of older adults receiving flecainide (observational cohort)【1】.

Clinical guidelines advise that flecainide should be avoided in individuals with structural heart disease, coronary artery disease, heart failure (NYHA class II–IV or left‑ventricular ejection fraction < 30–40 %), or significant conduction system disease【4】【5】【6】【3】.
The CAST randomized controlled trial demonstrated that flecainide use in patients with the above cardiac conditions markedly increases the risk of ventricular pro‑arrhythmia and overall mortality【5】【6】【2】.
For a 67‑year‑old male with atherosclerotic risk factors, a formal ischemia assessment (e.g., stress testing) is recommended before initiating flecainide【3】.

In patients with moderate to severe renal impairment (creatinine clearance < 35 mL/min), dose reduction of flecainide is required to avoid drug accumulation【3】.

When urinary symptoms arise in an older male on flecainide, the first step is to assess for common age‑related urological conditions such as benign prostatic hyperplasia, as these are far more prevalent than drug‑induced retention【1】.

Renal impairment markedly reduces flecainide clearance, increasing toxicity risk and requiring mandatory dose reduction for patients with creatinine clearance < 35–50 mL/min, although flecainide itself does not cause intrinsic renal injury. (ESC guideline recommendation) 7

In severe renal impairment (creatinine clearance ≤ 35 mL/min), the initial flecainide dose should be limited to 100 mg once daily, with frequent plasma‑level monitoring to prevent toxic accumulation. (ESC guideline recommendation) 7
For moderate renal dysfunction (creatinine clearance 35–50 mL/min), the European Society of Cardiology (ESC) guidelines contraindicate flecainide use unless a carefully dose‑adjusted regimen is applied. (ESC guideline recommendation) 7

Baseline assessment of renal function (creatinine clearance) must be performed before initiating flecainide therapy. (ESC guideline recommendation) 7